Download PDF
Semin Thromb Hemost 2020; 46(03): 264-274
DOI: 10.1055/s-0039-1697930
Review Article

Drug-Induced Thrombocytopenia: Mechanisms and Laboratory Diagnostics

Elisa Danese‡   *
1   Section of Clinical Biochemistry, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy
,
Martina Montagnana   *
1   Section of Clinical Biochemistry, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy
,
Emmanuel J. Favaloro
2   Department of Haematology, Sydney Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research, NSW Health Pathology, Westmead Hospital, Westmead, Australia
,
Giuseppe Lippi
1   Section of Clinical Biochemistry, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Thrombocytopenia is a condition characterized by a decreased number of platelets in peripheral blood, which can be caused by a myriad of both congenital and acquired disorders. Drug-induced thrombocytopenia (DIT) deserves a special focus since its cumulative incidence can be as high as 10 cases per million population per year, with a prevalence of approximately 25% in critically ill patients. This condition is usually suspected following identification of an acute and severe decrease in platelet count, with values usually < 50 ×109/L, thus potentially exposing patients to an increased risk of developing spontaneous hemorrhages. Conversely, however, some drug-related thrombocytopenias are instead (and perhaps counterintuitively) associated with increased thrombosis risk. Although a vast number of drugs have been implicated in DIT, the underlying pathogenetic mechanisms are essentially bifold, encompassing reduced platelet production due to bone marrow suppression (thus insufficient maturation or inefficient expansion of megakaryocytes, impaired release of platelets, or accelerated platelet apoptosis) or accelerated clearance of platelets from the circulation. This second form of DIT can be sustained by nonimmune, immune-mediated, or autoimmune mechanisms. An early and accurate diagnosis of DIT, which is crucial for reversing an otherwise unfavorable clinical outcome, is essentially based on the complete blood cell count, blood smear analysis, and performance of specific functional or immunochemical tests aimed at demonstrating the presence of antiplatelet antibodies.

Keywords

drug-induced thrombocytopenia - chemotherapy-induced thrombocytopenia - immune - nonimmune - heparin-induced thrombocytopenia - hapten-induced antibodies - drug-induced antibodies

* Contributed equally to this work.




Publication History

Publication Date:
28 September 2019 (online)

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Gauer RL, Braun MM. Thrombocytopenia. Am Fam Physician 2012; 85 (06) 612-622
    Google Scholar
  • 2 Smock KJ, Perkins SL. Thrombocytopenia: an update. Int J Lab Hematol 2014; 36 (03) 269-278
    Google Scholar
  • 3 Skipper MT, Rubak P, Stentoft J, Hvas AM, Larsen OH. Evaluation of platelet function in thrombocytopenia. Platelets 2018; 29 (03) 270-276
    Google Scholar
  • 4 Lippi G, Favaloro EJ, Buoro S. Platelet transfusion thresholds: how low can we go in respect to platelet counting?. Semin Thromb Hemost, This issue
    Google Scholar
  • 5 Kenney B, Stack G. Drug-induced thrombocytopenia. Arch Pathol Lab Med 2009; 133 (02) 309-314
    Google Scholar
  • 6 Carey PJ. Drug-induced myelosuppression: diagnosis and management. Drug Saf 2003; 26 (10) 691-706
    Google Scholar
  • 7 Aster RH. Drug-induced immune cytopenias. Toxicology 2005; 209 (02) 149-153
    Google Scholar
  • 8 Gale RP. Antineoplastic chemotherapy myelosuppression: mechanisms and new approaches. Exp Hematol 1985; 13 (Suppl. 16) 3-7
    Google Scholar
  • 9 Weycker D, Hatfield M, Grossman A. et al. Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice. BMC Cancer 2019; 19 (01) 151
    Google Scholar
  • 10 Hitron A, Steinke D, Sutphin S, Lawson A, Talbert J, Adams V. Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors. J Oncol Pharm Pract 2011; 17 (04) 312-319
    Google Scholar
  • 11 Goldberg GL, Gibbon DG, Smith HO, DeVictoria C, Runowicz CD, Burns ER. Clinical impact of chemotherapy-induced thrombocytopenia in patients with gynecologic cancer. J Clin Oncol 1994; 12 (11) 2317-2320
    Google Scholar
  • 12 Hashiguchi Y, Fukuda T, Ichimura T. et al. Chemotherapy-induced thrombocytopenia and clinical bleeding in patients with gynecologic malignancy. Eur J Gynaecol Oncol 2015; 36 (02) 168-173
    Google Scholar
  • 13 Majhail NS, Lichtin AE. What is the best way to determine if thrombocytopenia in a patient on multiple medications is drug-induced?. Cleve Clin J Med 2002; 69 (03) 259-262
    Google Scholar
  • 14 Iancu-Rubin C, Gajzer D, Mosoyan G, Feller F, Mascarenhas J, Hoffman R. Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation. Exp Hematol 2012; 40 (07) 564-574
    Google Scholar
  • 15 Chang JK, Li CJ, Wu SC. et al. Effects of anti-inflammatory drugs on proliferation, cytotoxicity and osteogenesis in bone marrow mesenchymal stem cells. Biochem Pharmacol 2007; 74 (09) 1371-1382
    Google Scholar
  • 16 Von Drygalski A, Curtis BR, Bougie DW. et al. Vancomycin-induced immune thrombocytopenia. N Engl J Med 2007; 356 (09) 904-910
    Google Scholar
  • 17 Kuter DJ, Tillotson GS. Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid. Pharmacotherapy 2001; 21 (08) 1010-1013
    Google Scholar
  • 18 Wang Y, Smith KP. Safety of alternative antiviral agents for neonatal herpes simplex virus encephalitis and disseminated infection. J Pediatr Pharmacol Ther 2014; 19 (02) 72-82
    Google Scholar
  • 19 Danziger-Isakov L, Mark Baillie G. Hematologic complications of anti-CMV therapy in solid organ transplant recipients. Clin Transplant 2009; 23 (03) 295-304
    Google Scholar
  • 20 Kowdley KV. Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol 2005; 39 (1, Suppl): S3-S8
    Google Scholar
  • 21 Nosari A, Marbello L, De Carlis LG. et al. Bone marrow hypoplasia complicating tacrolimus (FK506) therapy. Int J Hematol 2004; 79 (02) 130-132
    Google Scholar
  • 22 Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34 (08) 1081-1085
    Google Scholar
  • 23 Leung M, Piatkov I, Rochester C, Boyages SC, Leong RW. Normal thiopurine methyltransferase phenotype testing in a Crohn disease patient with azathioprine induced myelosuppression. Intern Med J 2009; 39 (02) 121-126
    Google Scholar
  • 24 Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46 (02) 149-154
    Google Scholar
  • 25 Greinacher A, Fuerll B, Zinke H. et al. Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia. Blood 2009; 114 (06) 1250-1253
    Google Scholar
  • 26 Breton-Gorius J, Vainchenker W. Expression of platelet proteins during the in vitro and in vivo differentiation of megakaryocytes and morphological aspects of their maturation. Semin Hematol 1986; 23 (01) 43-67
    Google Scholar
  • 27 Perdomo J, Yan F, Ahmadi Z, Jiang XM, Stocker R, Chong BH. Quinine-induced thrombocytopenia: drug-dependent GPIb/IX antibodies inhibit megakaryocyte and proplatelet production in vitro. Blood 2011; 117 (22) 5975-5986
    Google Scholar
  • 28 Kile BT. The role of apoptosis in megakaryocytes and platelets. Br J Haematol 2014; 165 (02) 217-226
    Google Scholar
  • 29 Debrincat MA, Pleines I, Lebois M. et al. BCL-2 is dispensable for thrombopoiesis and platelet survival. Cell Death Dis 2015; 6: e1721
    Google Scholar
  • 30 Kaefer A, Yang J, Noertersheuser P. et al. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia. Cancer Chemother Pharmacol 2014; 74 (03) 593-602
    Google Scholar
  • 31 Pasikhova Y, Ludlow SP. Fluconazole associated agranulocytosis and thrombocytopenia. Int J Clin Pharm 2014; 36 (02) 268-270
    Google Scholar
  • 32 Baker GR, Levin J. Transient thrombocytopenia produced by administration of macrophage colony-stimulating factor: investigations of the mechanism. Blood 1998; 91 (01) 89-99
    Google Scholar
  • 33 Cole AP. Transient thrombocytopenia in a child on sodium valproate. Dev Med Child Neurol 1978; 20 (04) 487-490
    Google Scholar
  • 34 Coto-Segura P, Galache C, Santos-Juanes J, Mallo-García S, Curto-Iglesias JR. Transient thrombocytopenia probably induced by isotretinoin [in Spanish]. Actas Dermosifiliogr 2008; 99 (09) 743-744
    Google Scholar
  • 35 Yang CW, Yen HH, Su WW, Chen YY, Soon MS. Profound transient thrombocytopenia associated with 90Yttrium microsphere therapy for inoperable hepatoma. South Med J 2010; 103 (12) 1264-1268
    Google Scholar
  • 36 Platelets on the Web. Drug-Induced Thrombocytopenia. Accessed May 11, 2019 at: https://www.ouhsc.edu/platelets/ditp.html
    Google Scholar
  • 37 George JN, Sadler JE, Lämmle B. Platelets: thrombotic thrombocytopenic purpura. Hematology (Am Soc Hematol Educ Program) 2002; 315-334
    Google Scholar
  • 38 Newland AC, Macey MG. Immune thrombocytopenia and Fc receptor-mediated phagocyte function. Ann Hematol 1994; 69 (02) 61-67
    Google Scholar
  • 39 Bougie DW, Nayak D, Boylan B, Newman PJ, Aster RH. Drug-dependent clearance of human platelets in the NOD/scid mouse by antibodies from patients with drug-induced immune thrombocytopenia. Blood 2010; 116 (16) 3033-3038
    Google Scholar
  • 40 Liang SX, Pinkevych M, Khachigian LM, Parish CR, Davenport MP, Chong BH. Drug-induced thrombocytopenia: development of a novel NOD/SCID mouse model to evaluate clearance of circulating platelets by drug-dependent antibodies and the efficacy of IVIG. Blood 2010; 116 (11) 1958-1960
    Google Scholar
  • 41 Chong BH, Isaacs A. Heparin-induced thrombocytopenia: what clinicians need to know. Thromb Haemost 2009; 101 (02) 279-283
    Google Scholar
  • 42 Olsson B, Andersson PO, Jernås M. et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003; 9 (09) 1123-1124
    Google Scholar
  • 43 Visentin GP, Liu CY. Drug-induced thrombocytopenia. Hematol Oncol Clin North Am 2007; 21 (04) 685-696 , vi
    Google Scholar
  • 44 Meng X, Jenkins RE, Berry NG. et al. Direct evidence for the formation of diastereoisomeric benzylpenicilloyl haptens from benzylpenicillin and benzylpenicillenic acid in patients. J Pharmacol Exp Ther 2011; 338 (03) 841-849
    Google Scholar
  • 45 Aljitawi OS, Krishnan K, Curtis BR, Bougie DW, Aster RH. Serologically documented loracarbef (Lorabid)-induced immune thrombocytopenia. Am J Hematol 2003; 73 (01) 41-43
    Google Scholar
  • 46 Grossjohann B, Eichler P, Greinacher A, Santoso S, Kroll H. Ceftriaxone causes drug-induced immune thrombocytopenia and hemolytic anemia: characterization of targets on platelets and red blood cells. Transfusion 2004; 44 (07) 1033-1040
    Google Scholar
  • 47 Verrotti A, Scaparrotta A, Grosso S, Chiarelli F, Coppola G. Anticonvulsant drugs and hematological disease. Neurol Sci 2014; 35 (07) 983-993
    Google Scholar
  • 48 Lippi G, Plebani M. EDTA-dependent pseudothrombocytopenia: further insights and recommendations for prevention of a clinically threatening artifact. Clin Chem Lab Med 2012; 50 (08) 1281-1285
    Google Scholar
  • 49 Aster RH, Curtis BR, McFarland JG, Bougie DW. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost 2009; 7 (06) 911-918
    Google Scholar
  • 50 Asvadi P, Ahmadi Z, Chong BH. Drug-induced thrombocytopenia: localization of the binding site of GPIX-specific quinine-dependent antibodies. Blood 2003; 102 (05) 1670-1677
    Google Scholar
  • 51 Burgess JK, Lopez JA, Berndt MC, Dawes I, Chesterman CN, Chong BH. Quinine-dependent antibodies bind a restricted set of epitopes on the glycoprotein Ib-IX complex: characterization of the epitopes. Blood 1998; 92 (07) 2366-2373
    Google Scholar
  • 52 Chong BH, Du XP, Berndt MC, Horn S, Chesterman CN. Characterization of the binding domains on platelet glycoproteins Ib-IX and IIb/IIIa complexes for the quinine/quinidine-dependent antibodies. Blood 1991; 77 (10) 2190-2199
    Google Scholar
  • 53 Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007; 357 (06) 580-587
    Google Scholar
  • 54 Chong BH, Choi PY, Khachigian L, Perdomo J. Drug-induced immune thrombocytopenia. Hematol Oncol Clin North Am 2013; 27 (03) 521-540
    Google Scholar
  • 55 Koh CY, Modahl CM, Kulkarni N, Kini RM. Toxins are an excellent source of therapeutic agents against cardiovascular diseases. Semin Thromb Hemost 2018; 44 (07) 691-706
    Google Scholar
  • 56 Aster RH. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest 2005; 127 (2, Suppl): 53S-59S
    Google Scholar
  • 57 RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997; 96 (05) 1445-1453
    Google Scholar
  • 58 Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338 (21) 1488-1497
    Google Scholar
  • 59 Koster A, Morshuis M, Birschmann I. Abciximab/heparin during acute heparin-induced thrombocytopenia: a word of caution. Ann Thorac Surg 2018; 106 (01) 309
    Google Scholar
  • 60 Bougie DW, Wilker PR, Wuitschick ED. et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002; 100 (06) 2071-2076
    Google Scholar
  • 61 Billheimer JT, Dicker IB, Wynn R. et al. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood 2002; 99 (10) 3540-3546
    Google Scholar
  • 62 Lerner W, Caruso R, Faig D, Karpatkin S. Drug-dependent and non-drug-dependent antiplatelet antibody in drug-induced immunologic thrombocytopenic purpura. Blood 1985; 66 (02) 306-311
    Google Scholar
  • 63 Aster RH. Can drugs cause autoimmune thrombocytopenic purpura?. Semin Hematol 2000; 37 (03) 229-238
    Google Scholar
  • 64 Neau D, Bonnet F, Michaud M. et al. Immune thrombocytopenic purpura after recombinant hepatitis B vaccine: retrospective study of seven cases. Scand J Infect Dis 1998; 30 (02) 115-118
    Google Scholar
  • 65 Nieminen U, Peltola H, Syrjälä MT, Mäkipernaa A, Kekomäki R. Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. A report on 23 patients. Acta Paediatr 1993; 82 (03) 267-270
    Google Scholar
  • 66 Griem P, Gleichmann E. Metal ion induced autoimmunity. Curr Opin Immunol 1995; 7 (06) 831-838
    Google Scholar
  • 67 Prechel M, Walenga JM. Heparin-induced thrombocytopenia: an update. Semin Thromb Hemost 2012; 38 (05) 483-496
    Google Scholar
  • 68 Jang IK, Hursting MJ. When heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation 2005; 111 (20) 2671-2683
    Google Scholar
  • 69 Favaloro EJ, McCaughan G, Pasalic L. Clinical and laboratory diagnosis of heparin induced thrombocytopenia: an update. Pathology 2017; 49 (04) 346-355
    Google Scholar
  • 70 Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005; 94 (01) 132-135
    Google Scholar
  • 71 Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163 (20) 2518-2524
    Google Scholar
  • 72 Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344 (17) 1286-1292
    Google Scholar
  • 73 Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135 (07) 502-506
    Google Scholar
  • 74 Smythe MA, Stephens JL, Mattson JC. Delayed-onset heparin-induced thrombocytopenia. Ann Emerg Med 2005; 45 (04) 417-419
    Google Scholar
  • 75 Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 2002; 136 (03) 210-215
    Google Scholar
  • 76 Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4 (04) 759-765
    Google Scholar
  • 77 Arepally GM. Heparin-induced thrombocytopenia. Blood 2017; 129 (21) 2864-2872
    Google Scholar
  • 78 Wazny LD, Ariano RE. Evaluation and management of drug-induced thrombocytopenia in the acutely ill patient. Pharmacotherapy 2000; 20 (03) 292-307
    Google Scholar
  • 79 Arnold DM, Kukaswadia S, Nazi I. et al. A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia. J Thromb Haemost 2013; 11 (01) 169-176
    Google Scholar
  • 80 Heikal NM, Smock KJ. Laboratory testing for platelet antibodies. Am J Hematol 2013; 88 (09) 818-821
    Google Scholar
  • 81 Arnold DM, Nazi I, Warkentin TE. et al. Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev 2013; 27 (03) 137-145
    Google Scholar
  • 82 Visentin GP, Wolfmeyer K, Newman PJ, Aster RH. Detection of drug-dependent, platelet-reactive antibodies by antigen-capture ELISA and flow cytometry. Transfusion 1990; 30 (08) 694-700
    Google Scholar
  • 83 Bougie D, Aster R. Immune thrombocytopenia resulting from sensitivity to metabolites of naproxen and acetaminophen. Blood 2001; 97 (12) 3846-3850
    Google Scholar
  • 84 Arnold DM, Curtis BR, Bakchoul T. Platelet Immunology Scientific Subcommittee of the International Society on Thrombosis and Hemostasis. Recommendations for standardization of laboratory testing for drug-induced immune thrombocytopenia: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13 (04) 676-678
    Google Scholar
  • 85 Amiral J, Seghatchian J. An update on evidence based diagnostic and confirmatory testing strategies for heparin induced thrombocytopenia using combined immunological and functional assays. Transfus Apheresis Sci 2018; 57 (06) 804-811
    Google Scholar
  • 86 Favaloro EJ. Laboratory tests for identification or exclusion of heparin induced thrombocytopenia: HIT or miss?. Am J Hematol 2018; 93 (02) 308-314
    Google Scholar
  • 87 Favaloro EJ, McCaughan G, Mohammed S. et al. HIT or miss? A comprehensive contemporary investigation of laboratory tests for heparin induced thrombocytopenia. Pathology 2018; 50 (04) 426-436
    Google Scholar
  • 88 Eekels JJM, Althaus K, Bakchoul T. et al. An international external quality assessment for laboratory diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2019; 17 (03) 525-531
    Google Scholar
  • 89 Lau KKE, Mohammed S, Pasalic L, Favaloro EJ. Laboratory testing protocols for heparin-induced thrombocytopenia (HIT) testing. Methods Mol Biol 2017; 1646: 227-243
    Google Scholar
  • 90 Omer T, Mullaguri N, George P, Newey CR. False-negative platelet factor 4 antibodies and serotonin release assay and the utility of repeat testing in the diagnosis of heparin-induced thrombocytopenia and thrombosis. Case Rep Hematol 2019; 2019: 1585014
    Google Scholar
  • 91 Bakchoul T, Zöllner H, Greinacher A. Current insights into the laboratory diagnosis of HIT. Int J Lab Hematol 2014; 36 (03) 296-305
    Google Scholar
  • 92 Warkentin TE, Cook RJ, Marder VJ. et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005; 106 (12) 3791-3796
    Google Scholar
  • 93 Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 2012; 120 (20) 4160-4167
    Google Scholar
  • 94 Minet V, Dogné JM, Mullier F. Functional assays in the diagnosis of heparin-induced thrombocytopenia: a review. Molecules 2017; 22 (04) E617
    Google Scholar
  • 95 Warkentin TE, Arnold DM, Nazi I, Kelton JG. The platelet serotonin-release assay. Am J Hematol 2015; 90 (06) 564-572
    Google Scholar
  • 96 Pandya KA, Johnson EG, Davis GA, Padmanabhan A. Serotonin release assay (SRA)-negative HIT, a newly recognized entity: implications for diagnosis and management. Thromb Res 2018; 172: 169-171
    Google Scholar
  • 97 Vayne C, Guery EA, Kizlik-Masson C. et al. Beneficial effect of exogenous platelet factor 4 for detecting pathogenic heparin-induced thrombocytopenia antibodies. Br J Haematol 2017; 179 (05) 811-819
    Google Scholar
  • 98 Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991; 66 (06) 734-736
    Google Scholar
  • 99 Leo A, Winteroll S. Laboratory diagnosis of heparin-induced thrombocytopenia and monitoring of alternative anticoagulants. Clin Diagn Lab Immunol 2003; 10 (05) 731-740
    Google Scholar
  • 100 Seghatchian J. Accurate and rapid data -Driven flowcytometry functional assays for improved diagnostic / prognostic of ITP and HIT disorders. Transfus Apheresis Sci 2018; 57 (06) 799
    Google Scholar
  • 101 Ivetic N, Arnold DM, Smith JW, Huynh A, Kelton JG, Nazy I. A platelet viability assay (PVA) for the diagnosis of heparin-induced thrombocytopenia. Platelets 2019; (e-pub ahead of print) DOI: 10.1080/09537104.2018.1562169.
    Google Scholar
  • 102 Morel-Kopp MC, Mullier F, Gkalea V. et al; subcommittee on platelet immunology. Heparin-induced multi-electrode aggregometry method for heparin-induced thrombocytopenia testing: communication from the SSC of the ISTH. J Thromb Haemost 2016; 14 (12) 2548-2552
    Google Scholar
  • 103 Morel-Kopp MC, Tan CW, Brighton TA. et al; ASTH Clinical Trials Group. Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT: results of a large Australian study. Thromb Haemost 2012; 107 (03) 575-583
    Google Scholar
  • 104 Nasraway SA, Shorr AF, Kuter DJ, O'Grady N, Le VH, Cammarata SK. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis 2003; 37 (12) 1609-1616
    Google Scholar
  • 105 Minson Q, Gentry CA. Analysis of linezolid-associated hematologic toxicities in a large veterans affairs medical center. Pharmacotherapy 2010; 30 (09) 895-903
    Google Scholar
  • 106 Reichardt P, Handrick W, Linke A, Schille R, Kiess W. Leukocytopenia, thrombocytopenia and fever related to piperacillin/tazobactam treatment--a retrospective analysis in 38 children with cystic fibrosis. Infection 1999; 27 (06) 355-356
    Google Scholar
  • 107 Ruiz-Irastorza G, Barreiro G, Aguirre C. Reversible bone marrow depression by high-dose piperacillin/tazobactam. Br J Haematol 1996; 95 (04) 611-612
    Google Scholar
  • 108 Yamanouchi J, Hato T, Shiraishi S, Takeuchi K, Yakushijin Y, Yasukawa M. Vancomycin-induced immune thrombocytopenia proven by the detection of vancomycin-dependent anti-platelet antibody with flow cytometry. Intern Med 2016; 55 (20) 3035-3038
    Google Scholar
  • 109 Kaufman DW, Kelly JP, Johannes CB. et al. Acute thrombocytopenic purpura in relation to the use of drugs. Blood 1993; 82 (09) 2714-2718
    Google Scholar
  • 110 Pedersen-Bjergaard U, Andersen M, Hansen PB. Drug-specific characteristics of thrombocytopenia caused by non-cytotoxic drugs. Eur J Clin Pharmacol 1998; 54 (9-10): 701-706
    Google Scholar
  • 111 Matsumoto K, Shigemi A, Ikawa K. et al. Risk factors for ganciclovir-induced thrombocytopenia and leukopenia. Biol Pharm Bull 2015; 38 (02) 235-238
    Google Scholar
  • 112 Razonable RR. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc 2011; 86 (10) 1009-1026
    Google Scholar
  • 113 Jin N, Lubner SJ, Mulkerin DL. et al. A phase II trial of a histone deacetylase inhibitor panobinostat in patients with low-grade neuroendocrine tumors. Oncologist 2016; 21 (07) 785-786
    Google Scholar
  • 114 Loo AS, Gerzenshtein L, Ison MG. Antimicrobial drug-induced thrombocytopenia: a review of the literature. Semin Thromb Hemost 2012; 38 (08) 818-829
    Google Scholar
  • 115 Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339 (07) 436-443
    Google Scholar
  • 116 Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338 (21) 1498-1505
    Google Scholar
  • 117 Tcheng JE, Kereiakes DJ, Lincoff AM. et al. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 2001; 104 (08) 870-875
    Google Scholar
  • 118 Curtis BR, Divgi A, Garritty M, Aster RH. Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug. J Thromb Haemost 2004; 2 (06) 985-992
    Google Scholar
  • 119 Al-Nouri ZL, Reese JA, Terrell DR, Vesely SK, George JN. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood 2015; 125 (04) 616-618
    Google Scholar
  • 120 Kosty MP, Hench PK, Tani P, McMillan R. Thrombocytopenia associated with auranofin therapy: evidence for a gold-dependent immunologic mechanism. Am J Hematol 1989; 30 (04) 236-239
    Google Scholar